Meeting
2011 ASCO Annual Meeting
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Authors
J. H. Strickler
Duke University Medical Center, Durham, NC
J. H. Strickler , A. L. Cohn , C. Arrowood , S. Haley , M. Morse , H. Uronis , G. C. Blobe , S. D. Hsu , Y. Zafar , H. Hurwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00920868
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3586)
Abstract #
3586
Poster Bd #
16B
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
First Author: Fatima A. Rangwala
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2021 Gastrointestinal Cancers Symposium
Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.
First Author: Hideaki Bando
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji